Stock analysts at StockNews.com initiated coverage on shares of Arbutus Biopharma (NASDAQ:ABUS – Get Rating) in a report issued on Thursday. The firm set a “hold” rating on the biopharmaceutical company’s stock.
Other analysts also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Arbutus Biopharma in a research report on Friday, March 3rd. Chardan Capital reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Arbutus Biopharma in a research report on Friday, March 3rd.
Arbutus Biopharma Price Performance
Shares of NASDAQ:ABUS opened at $3.03 on Thursday. The company has a quick ratio of 4.60, a current ratio of 4.60 and a debt-to-equity ratio of 0.04. Arbutus Biopharma has a 52-week low of $1.85 and a 52-week high of $3.22. The company has a 50 day moving average of $2.80 and a two-hundred day moving average of $2.49. The company has a market capitalization of $492.59 million, a price-to-earnings ratio of -6.45 and a beta of 2.26.
Institutional Investors Weigh In On Arbutus Biopharma
About Arbutus Biopharma
Arbutus Biopharma Corp. is a biopharmaceutical company. It engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.
- Get a free copy of the StockNews.com research report on Arbutus Biopharma (ABUS)
- Meta Platforms: Efficiency Gains Momentum, Stock Accelerates
- Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
- SentinelOne: Reversal In-Play For Cybersecurity Stocks
- Is Sportradar Group A Growth Stock To Bet On In 2023?
- Strong Guidance says Boeing is Ready for Takeoff
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.